INCY vs ROIV: Incyte and Roivant Sciences compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Roivant Sciences is the larger company, worth $27.2B, about 1.2 times Incyte.
- Incyte grew revenue faster over the last year (+20.9% vs -33.5%).
- Incyte keeps more of each dollar of revenue as operating profit (30.1% vs -7914.8%).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | INCY | ROIV |
|---|---|---|
| Market cap | $21.8B | $27.2B |
| Share price | $112.79 | $35.44 |
| Revenue (last fiscal year) | $5.1B | $8M |
| Free cash flow (last fiscal year) | — | -$759M |
| Revenue growth, last year | +20.9% | -33.5% |
| Revenue growth per year, last 5 fiscal years | +14.5% | -37.8% |
| Operating margin | 30.1% | -7914.8% |
| Net margin | 26.7% | -3535.0% |
| Return on equity | 25.5% | -6.3% |
| P/E (trailing) | 15.4x | — |
| Price / free cash flow | 16.1x | — |
| EV / EBITDA | 9.50x | — |
| FCF growth the price implies | — | — |
| Dividend yield | — | — |
| Debt / equity | 0.31x | 0.09x |
| Fundamental grade | A | F |
| Superinvestors holding it | 3 | 7 |
| Insider purchases, last 12 months | 4 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Incyte
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $3.0B | $568M | 19.6% |
| 2022 | $3.4B | $892M | 17.1% |
| 2023 | $3.7B | — | 16.8% |
| 2024 | $4.2B | — | 1.4% |
| 2025 | $5.1B | — | 29.5% |
Roivant Sciences
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2022 | $55M | -$695M | -2444.8% |
| 2023 | $32M | -$856M | -2875.9% |
| 2024 | $33M | -$767M | 13746.9% |
| 2025 | $29M | -$844M | -3453.3% |
| 2026 | $8M | -$759M | -6235.7% |
Where the revenue comes from
Incyte · by products, 2025
JAKAFI$3.1B60%
OPZELURA$678M13%
JAKAVI Royalty Revenues$458M9%
NIKTIMVO$152M3%
Milestone and contract revenues$150M3%
OLUMIANT Royalty Revenues$145M3%
Roivant Sciences · by products, 2024
Product revenue, net$75M60%
License, milestone and other revenue$50M40%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open INCY in InvestinglyQuestions
Which is bigger, Incyte or Roivant Sciences?
Roivant Sciences (ROIV), at $27.2B against $21.8B.
Which grows faster, INCY or ROIV?
Incyte: revenue grew +20.9% over the last year, against -33.5%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.